WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "e45473a0-fbf4-4095-b4e9-f86071b662bc"}, "_deposit": {"created_by": 3, "id": "26987", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "26987"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00026987", "sets": ["1763"]}, "author_link": ["22059", "45713", "45709", "45712", "45710", "45711"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2008-01-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "84", "bibliographicPageStart": "79", "bibliographicVolumeNumber": "34", "bibliographic_titles": [{"bibliographic_title": "医療薬学"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Epirubicin-cyclophosphamide (EC) and fluorouracil-epirubicin-cyclophosphamide (FEC),2 epirubicin-based regimens,are often switched to docetaxel (DOC) in chemotherapy before and after breast surgery.As nail discoloration had been frequently observed during these breast cancer chemotherapy regimens,we investigated adverse drug events in nails.Drug adverse events were observed in the nails of 87% of patients treated with EC,in 83% treated with FEC,and 58% treated with DOC following the switch from EC or FEC.With regard to the time of onset,most nail discoloration appeared after second or third course of chemotherapy with EC or FEC.Adverse drug events differed depending on the chemotherapy regimen.Nail discoloration was nearly all specific to EC and FEC and nail bed pain,onycholysis,and koilonychias tended to occur with DOC.Though most adverse drug events in the nails were mild,any of Grade 2 (CTCAE v 3.0) occurring would have impaired quality of life and caused psychological stress.Therefore,pharmacists should inform patients receiving these chemotherapies of the possibility of adverse drug events in the nails and observe them carefully.They should also recommend consultation with a dermatologist as early as possible if Grade 2 adverse drug events should occur.", "subitem_description_type": "Abstract"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本医療薬学会 = Japanese Society of Phamaceutical Health care and Sciences"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.5649/jjphcs.34.79", "subitem_relation_type_select": "DOI"}}]}, "item_4_relation_28": {"attribute_name": "関連URI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.jsphcs.jp/", "subitem_relation_type_select": "URI"}}, {"subitem_relation_type_id": {"subitem_relation_type_id_text": "http://ci.nii.ac.jp/naid/110006546904", "subitem_relation_type_select": "URI"}}, {"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://japanlinkcenter.org/JST.JSTAGE/jjphcs/34.79", "subitem_relation_type_select": "URI"}}]}, "item_4_rights_23": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright (c) 2009 日本医療薬学会"}]}, "item_4_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11527197", "subitem_source_identifier_type": "NCID"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1346-342X", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "竹下, 英里"}], "nameIdentifiers": [{"nameIdentifier": "45709", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "橋本, 秀子"}], "nameIdentifiers": [{"nameIdentifier": "45710", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石本, 聖"}], "nameIdentifiers": [{"nameIdentifier": "45711", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "河原, 昌美"}], "nameIdentifiers": [{"nameIdentifier": "45712", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "橋本, 政和"}], "nameIdentifiers": [{"nameIdentifier": "45713", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "宮本, 謙一"}], "nameIdentifiers": [{"nameIdentifier": "22059", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30100514", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030100514"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "HO-PR-MIYAMOTO-K-79.pdf", "filesize": [{"value": "78.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 78100.0, "url": {"label": "HO-PR-MIYAMOTO-K-79.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/26987/files/HO-PR-MIYAMOTO-K-79.pdf"}, "version_id": "a72a2872-8eea-4d2f-9f3c-daad87875e87"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "breeast cancer chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "fluorouracil", "subitem_subject_scheme": "Other"}, {"subitem_subject": "epirubicin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cyclophosphamide", "subitem_subject_scheme": "Other"}, {"subitem_subject": "docetaxel", "subitem_subject_scheme": "Other"}, {"subitem_subject": "nail discoloration", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "乳がん化学療法における爪に対する副作用の実態調査", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "乳がん化学療法における爪に対する副作用の実態調査"}, {"subitem_title": "Investigation of Adverse Drug Events in Nails during Breast Cancer Chemotherapy", "subitem_title_language": "en"}]}, "item_type_id": "4", "owner": "3", "path": ["1763"], "permalink_uri": "http://hdl.handle.net/2297/28422", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-05"}, "publish_date": "2017-10-05", "publish_status": "0", "recid": "26987", "relation": {}, "relation_version_is_last": true, "title": ["乳がん化学療法における爪に対する副作用の実態調査"], "weko_shared_id": -1}
乳がん化学療法における爪に対する副作用の実態調査
http://hdl.handle.net/2297/28422
http://hdl.handle.net/2297/28422a148ecfa-ea61-4185-a848-23a3734a0c59
名前 / ファイル | ライセンス | アクション |
---|---|---|
HO-PR-MIYAMOTO-K-79.pdf (78.1 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-05 | |||||
タイトル | ||||||
タイトル | 乳がん化学療法における爪に対する副作用の実態調査 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Investigation of Adverse Drug Events in Nails during Breast Cancer Chemotherapy | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
竹下, 英里
× 竹下, 英里× 橋本, 秀子× 石本, 聖× 河原, 昌美× 橋本, 政和× 宮本, 謙一 |
|||||
書誌情報 |
医療薬学 巻 34, 号 1, p. 79-84, 発行日 2008-01-10 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1346-342X | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA11527197 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.5649/jjphcs.34.79 | |||||
出版者 | ||||||
出版者 | 日本医療薬学会 = Japanese Society of Phamaceutical Health care and Sciences | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Epirubicin-cyclophosphamide (EC) and fluorouracil-epirubicin-cyclophosphamide (FEC),2 epirubicin-based regimens,are often switched to docetaxel (DOC) in chemotherapy before and after breast surgery.As nail discoloration had been frequently observed during these breast cancer chemotherapy regimens,we investigated adverse drug events in nails.Drug adverse events were observed in the nails of 87% of patients treated with EC,in 83% treated with FEC,and 58% treated with DOC following the switch from EC or FEC.With regard to the time of onset,most nail discoloration appeared after second or third course of chemotherapy with EC or FEC.Adverse drug events differed depending on the chemotherapy regimen.Nail discoloration was nearly all specific to EC and FEC and nail bed pain,onycholysis,and koilonychias tended to occur with DOC.Though most adverse drug events in the nails were mild,any of Grade 2 (CTCAE v 3.0) occurring would have impaired quality of life and caused psychological stress.Therefore,pharmacists should inform patients receiving these chemotherapies of the possibility of adverse drug events in the nails and observe them carefully.They should also recommend consultation with a dermatologist as early as possible if Grade 2 adverse drug events should occur. | |||||
権利 | ||||||
権利情報 | Copyright (c) 2009 日本医療薬学会 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | http://www.jsphcs.jp/ | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | http://ci.nii.ac.jp/naid/110006546904 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://japanlinkcenter.org/JST.JSTAGE/jjphcs/34.79 |